Related Experiment Videos
Postoperative topical mitomycin C in conjunctival squamous cell neoplasia
E K Akpek1, D Ertoy, D Kalayci
1Cornea and External Disease Service, The Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287-9238, USA.
Cornea
|January 23, 1999
Summary
Topical mitomycin C effectively prevented recurrences of conjunctival squamous cell neoplasia after incomplete surgical excision. This treatment showed a favorable safety profile in a small patient cohort.
Area of Science:
- Ophthalmology
- Oncology
- Dermatology
Background:
- Conjunctival squamous cell neoplasia is a malignancy affecting the eye's surface.
- Incomplete surgical excision can lead to local tumor recurrence.
- Adjuvant therapies are sought to improve outcomes after surgery.
Purpose of the Study:
- To evaluate the efficacy of topical mitomycin C (MMC) in preventing local recurrences.
- To assess the safety and tolerability of adjuvant MMC in this setting.
Main Methods:
- A case series of four patients with incompletely excised conjunctival intraepithelial neoplasia.
- Postoperative treatment with topical mitomycin C 0.02% three times daily for two weeks.
- Clinical follow-up to assess for tumor recurrence and side effects.
Main Results:
- All four patients remained free of detectable tumors at a mean follow-up of 20 months.
- Transient side effects included mild discomfort, redness, and photophobia.
- Punctate epithelial keratopathy was observed but resolved upon medication cessation.
Conclusions:
- Topical mitomycin C appears to be a beneficial adjuvant therapy for preventing recurrence.
- It offers a potential solution for managing incomplete excisions of conjunctival squamous cell neoplasia.
- Further studies are warranted to confirm these findings in larger cohorts.